179 related articles for article (PubMed ID: 27300551)
21. Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer.
Zhu ZF; Ma HL; Fan M; Bao Y; Zhuang TT; Chen M; Jiang GL; Fu XL
Technol Cancer Res Treat; 2014 Jun; 13(3):269-75. PubMed ID: 24066952
[TBL] [Abstract][Full Text] [Related]
22. Modern induction chemotherapy before chemoradiation for bulky locally-advanced nonsmall cell lung cancer improves survival.
Ahmed I; Ferro A; Baby R; Malhotra J; Cohler A; Langenfeld J; Aisner J; Zou W; Jabbour SK
J Cancer Res Ther; 2016; 12(2):952-8. PubMed ID: 27461680
[TBL] [Abstract][Full Text] [Related]
23. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre.
Spencer A; Williams J; Samuel R; Boon IS; Clarke K; Jain P
Cancer Treat Res Commun; 2021; 29():100460. PubMed ID: 34598059
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer.
Minami-Shimmyo Y; Ohe Y; Yamamoto S; Sumi M; Nokihara H; Horinouchi H; Yamamoto N; Sekine I; Kubota K; Tamura T
J Thorac Oncol; 2012 Jan; 7(1):177-82. PubMed ID: 22134071
[TBL] [Abstract][Full Text] [Related]
25. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
Fournel P; Vergnenégre A; Robinet G; Léna H; Gervais R; Le Caer H; Souquet PJ; Chavaillon JM; Bozonnat MC; Daurès JP; Chouaid C; Martel-Lafay I;
Eur J Cancer; 2016 Jan; 52():181-7. PubMed ID: 26689864
[TBL] [Abstract][Full Text] [Related]
26. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
Katsui K; Ogata T; Watanabe K; Katayama N; Kuroda M; Kiura K; Hiraki T; Maeda Y; Toyooka S; Kanazawa S
Cancer Med; 2020 Jul; 9(13):4540-4549. PubMed ID: 32364685
[TBL] [Abstract][Full Text] [Related]
27. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
28. The Role of Additional Chemotherapy in Combination with Concurrent Chemoradiotherapy for Locally Advanced Inoperable Non-Small Cell Lung Cancer, a Systematic Review and Meta-Analysis of 12 Randomized Trials.
Ying M; Liu J; Zhou W; Weng K; Long B; Wang Y
Cancer Invest; 2019; 37(8):376-386. PubMed ID: 31474153
[TBL] [Abstract][Full Text] [Related]
29. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
30. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
[TBL] [Abstract][Full Text] [Related]
32. Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis.
Chang XJ; Wang ZT; Yang L
Mol Clin Oncol; 2016 Aug; 5(2):271-278. PubMed ID: 27446563
[TBL] [Abstract][Full Text] [Related]
33. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone.
Abe T; Saito S; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
Thorac Cancer; 2021 Jan; 12(2):245-250. PubMed ID: 33289347
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
35. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
[TBL] [Abstract][Full Text] [Related]
36. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
[TBL] [Abstract][Full Text] [Related]
37. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.
Ahn JS; Ahn YC; Kim JH; Lee CG; Cho EK; Lee KC; Chen M; Kim DW; Kim HK; Min YJ; Kang JH; Choi JH; Kim SW; Zhu G; Wu YL; Kim SR; Lee KH; Song HS; Choi YL; Sun JM; Jung SH; Ahn MJ; Park K
J Clin Oncol; 2015 Aug; 33(24):2660-6. PubMed ID: 26150444
[TBL] [Abstract][Full Text] [Related]
38. Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery: a single institution retrospective study.
Guan S; Ren K; Zhang X; Yan M; Li X; Zhao L
Radiat Oncol; 2023 Jul; 18(1):122. PubMed ID: 37491257
[TBL] [Abstract][Full Text] [Related]
39. A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.
Harris JP; Patel MI; Loo BW; Wakelee HA; Diehn M
Lung Cancer; 2017 Jun; 108():173-182. PubMed ID: 28625632
[TBL] [Abstract][Full Text] [Related]
40. Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis.
Kuang Y; Pierce CM; Chang HC; Sosinsky AZ; Deitz AC; Keller SM; Samkari A; Uyei J
Lung Cancer; 2022 Dec; 174():174-185. PubMed ID: 35717343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
